For the Inventor, By the Inventor

Enter assignee name

Freising, Germany

Pieris Pharmaceuticals Gmbh

USPTO Granted Patents = 36

CIPO Patents = 3

EPO Patents = 21

Trademarks = 3

Forward Citations = 73

Loading Chart...

Loading Chart...

57 inventors (with patents filed for the assignee):

Andrea Allersdorfer (17 out of 26 patents)

Marlon Hinner (14 out of 24 patents)

Christine Rothe (14 out of 26 patents)

4. Shane Olwill (14 out of 15 patents)

5. Rachida Siham Bel Aiba (14 out of 18 patents)

6. Alexander Wiedenmann (12 out of 22 patents)

7. Gabriele Matschiner (12 out of 21 patents)

8. Andreas Hohlbaum (11 out of 22 patents)

9. Laurent Audoly (10 out of 11 patents)

10. Martin Huelsmeyer (7 out of 12 patents)

11. Beverly Koller (5 out of 6 patents)

12. Stefan Trentmann (5 out of 9 patents)

13. Arne Skerra (4 out of 40 patents)

14. Timo Eichner (4 out of 4 patents)

15. Hendrik Gille (4 out of 6 patents)

36 patents: Sort by Forward Citations

1. 12195503 - Proteins specific for CD137 (2025-01-14),

2. 11919931 - Anti-cancer fusion polypeptide capable of binding both CD137 and glypican-3 (GPC3) (2024-03-05),

3. 11827681 - Muteins of human lipocalin 2 (Lcn2, hNGAL) with affinity for a given target (2023-11-28),

4. 11773147 - Lipocalin muteins with binding affinity for LAG-3 (2023-10-03),

5. 11382963 - Engineered T cells and uses therefor (2022-07-12),

6. 11382951 - Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptors (2022-07-12),

7. 11345728 - Specific-binding polypeptides and uses thereof (2022-05-31),

8. 11261221 - Proteins specific for CD137 (2022-03-01),

9. 11168119 - Lipocalin muteins with binding affinity for LAG-3 (2021-11-09),

10. 11034738 - Nucleic acid molecules encoding human neutrophil gelatinase-associated lipocalin (hNGAL) which bind angiopoietin-2 (Ang-2) (2021-06-15),

11. 11034737 - Proteins specific for calcitonin gene-related peptide (2021-06-15),

12. 10947284 - Fusion molecules (2021-03-16),

13. 10927156 - Human tear lipocalin muteins which specifically bind lymphocyte activation gene-3 (LAG3) and method of use thereof to stimulate an immune response (2021-02-23),

14. 10927154 - Multi-specific polypeptide useful for localized tumor immunomodulation (2021-02-23),

15. 10913778 - Anti-cancer fusion polypeptides, encoding nucleic acids and methods of using polypeptides (2021-02-09),

Pieris Pharmaceuticals GmbH is a clinical-stage biotechnology company focused on the discovery and development of Anticalin-based drugs. Anticalins are a novel class of therapeutics that are engineered proteins derived from human lipocalins. Pieris Pharmaceuticals is committed to advancing its pipeline of Anticalin-based drugs to address a wide range of diseases and disorders.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

36 Patents

#2 in Freising

#1,417 in Germany

#18,179 in the World

Freising, Germany

Pieris Pharmaceuticals Gmbh

Forward Citations = 73

57 inventors:

Andrea Allersdorfer (17 out of 26 patents)

Marlon Hinner (14 out of 24 patents)

Christine Rothe (14 out of 26 patents)

4. Shane Olwill (14 out of 15 patents)

5. Rachida Siham Bel Aiba (14 out of 18 patents)

Please report any incorrect information to support@idiyas.com

Loading…